Literature DB >> 182088

Endocrinopathy in thalassaemia major.

N McIntosh.   

Abstract

Pituitary, adrenal, and pancreatic functions were investigated in 9 patients with thalassaemia major. 9 a.m. plasma ACTH values were 148-480 pg/ml (normal range 15-70 pg/ml). Cortisol and growth hormone response to insulin-induced hypoglycaemia was normal in all. 24-hour urinary excretions of 17-ketosteroids and 17-hydroxycorticosteroids were normal. There was normal cortisol response to intramuscular injection of ACTH. In a physiological adrenal stimulation test there was a significantly smaller response to each physiological dose of tetracosactrin. 4 patients had diabetic glucose tolerance tests--none are clinically diabetic. The mean plasma glucose utilization constant (Kgl=2-02) is significantly smaller than normal. Plasma insulin response both in the oral and the intravenous glucose tolerance test was significantly smaller than normal. The data were consistent with severe and widespread impairment of endocrine function and a plausible explanation would be iron deposition in endocrine organs. It is suggested that pituitary hyperfunction of ACTH secretion is due to target organ unresponsiveness which can be shown in its early stages only by a physiological test of the adrenal cortex. Skin pigmentation in thalassaemia seems to be due to the melanophore-stimulating effect of this raised plasma ACTH.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182088      PMCID: PMC1545930          DOI: 10.1136/adc.51.3.195

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  27 in total

1.  IMMUNOASSAY OF SERUM GROWTH HORMONE IN ACROMEGALIC PATIENTS.

Authors:  M HARTOG; M A GAAFAR; B MEISSER; R FRASER
Journal:  Br Med J       Date:  1964-11-14

2.  COMPARISON OF SIXTY-SIX PATIENTS WITH THALASSEMIA MAJOR AND THIRTEEN PATIENTS WITH THALASSEMIA INTERMEDIA: INCLUDING EVALUATIONS OF GROWTH, DEVELOPMENT, MATURATION AND PROGNOSIS.

Authors:  M E ERLANDSON; R BRILLIANT; C H SMITH
Journal:  Ann N Y Acad Sci       Date:  1964-10-07       Impact factor: 5.691

3.  Immunoassay of insulin with insulin-antibody precipitate.

Authors:  C N HALES; P J RANDLE
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

4.  Studies on congenital hemolytic syndromes, IV. Gastrointestinal absorption of iron.

Authors:  M E ERLANDSON; B WALDEN; G STERN; M W HILGARTNER; J WEHMAN; C H SMITH
Journal:  Blood       Date:  1962-03       Impact factor: 22.113

5.  The isolation and structure of alpha- and beta-melanocyte-stimulating hormones from monkey pituitary glands.

Authors:  T H LEE; A B LERNER; V BUETTNER-JANUSCH
Journal:  J Biol Chem       Date:  1961-05       Impact factor: 5.157

6.  Comparison of duration of activity of corticotrophin-gelatin and corticotrophin-carboxymethylcellulose.

Authors:  M Friedman
Journal:  Br Med J       Date:  1967-08-12

7.  A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma.

Authors:  D MATTINGLY
Journal:  J Clin Pathol       Date:  1962-07       Impact factor: 3.411

8.  Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus.

Authors:  K LUNDBAEK
Journal:  Br Med J       Date:  1962-06-02

9.  Hypoglycemia: a potent stimulus to secretion of growth hormone.

Authors:  J ROTH; S M GLICK; R S YALOW
Journal:  Science       Date:  1963-05-31       Impact factor: 47.728

10.  ESTIMATION OF FERRIOXAMINE AND DESFERRIOXAMINE IN URINE.

Authors:  J FIELDING; M BRUNSTROEM
Journal:  J Clin Pathol       Date:  1964-07       Impact factor: 3.411

View more
  19 in total

1.  Beneficial effects of transfusing a patient with nontransfusion-dependent thalassaemia major.

Authors:  N McIntosh
Journal:  Arch Dis Child       Date:  1976-06       Impact factor: 3.791

2.  Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores.

Authors:  Eleni Drakonaki; Olympia Papakonstantinou; Thomas Maris; Artemis Vasiliadou; Alex Papadakis; Nicholas Gourtsoyiannis
Journal:  Eur Radiol       Date:  2005-08-16       Impact factor: 5.315

3.  Insulin dependent diabetes in thalassaemia.

Authors:  V De Sanctis; M G Zurlo; E Senesi; C Boffa; L Cavallo; F Di Gregorio
Journal:  Arch Dis Child       Date:  1988-01       Impact factor: 3.791

Review 4.  Stunted growth with more or less normal appearance.

Authors:  J R Bierich; H Enders; U Heinrich; R Huenges; M B Ranke; D Schoenberg
Journal:  Eur J Pediatr       Date:  1982-12       Impact factor: 3.183

5.  Primary hypothyroidism and the low T3 syndrome in thalassaemia major.

Authors:  A R Sabato; V de Sanctis; G Atti; L Capra; B Bagni; C Vullo
Journal:  Arch Dis Child       Date:  1983-02       Impact factor: 3.791

6.  Growth hormone secretion in polytransfused prepubertal patients with homozygous beta-thalassemia. Effect of long-term recombinant GH (recGH) therapy.

Authors:  A Masala; M M Atzeni; S Alagna; D Gallisai; C Burrai; M G Mela; P P Rovasio; P Gallo
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

7.  Sexual maturation and adrenal function in girls with thalassemia.

Authors:  C Pintor; S Loche; A Faedda; R Puggioni; A M Nurchi; V Fanni; R Corda
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

8.  Three-year prospective evaluation of glucose tolerance, beta-cell function and peripheral insulin sensitivity in non-diabetic patients with thalassemia major.

Authors:  M F Messina; F Lombardo; A Meo; M Miceli; M Wasniewska; M Valenzise; C Ruggeri; T Arrigo; F De Luca
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

9.  Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy.

Authors:  Somchit Jaruratanasirikul; Rarong Chareonmuang; Malai Wongcharnchailert; Vichai Laosombat; Pasuree Sangsupavanich; Kalaya Leetanaporn
Journal:  Eur J Pediatr       Date:  2007-09-25       Impact factor: 3.183

10.  The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.

Authors:  V De Sanctis; G D'Ascola; B Wonke
Journal:  Postgrad Med J       Date:  1986-09       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.